Experts at the BIO International Convention examine the growth of the 340B drug pricing program, duplicate discounts, patient access, and calls for greater transparency. […]
BIO 2026: 340B faces growing calls for transparency, patient-focused reform Read More »
From sickle cell disease to multiple sclerosis and childhood leukemia, patients and advocates reflected on becoming pioneers in therapies that are changing medicine. For
BIO 2026: ‘I am alive today because of biotech’ Read More »
What started as a conversation, in a bar, written on a napkin in 1976, between biochemist Dr. Herbert W. Boyer and investor Robert A.
After 50 years of biotech, can AI help answer the next impossible question? Read More »
Gary Sinise, Marcus Freeman, and BIO President & CEO John F. Crowley discussed leadership, resilience, and purpose at BIO 2026, drawing lessons from military
BIO 2026: Gary Sinise, Marcus Freeman on leadership, service, and resilience Read More »
The Reagan-Udall Foundation for the FDA just released a new report on strengthening early-stage drug development in the United States. The report reflects insights
New report details how U.S. can maintain biotech competitiveness Read More »
“AI systems will likely have a central role over the next several years in almost every component of the biotech ecosystem,” says Joe Franklin,
BIO 2026: What to know about the AI Summit Read More »
For decades, the United States has led the world in developing new medicines, turning scientific breakthroughs into treatments that save and improve lives. But
As policy ecosystem threatens biotech, new treatments could drop by over 50% in 20 years Read More »
Patient advocates are praising Virginia Gov. Abigail Spanberger’s May 19 veto of Prescription Drug Affordability Board (PDAB) legislation (HB 483 and SB 271), arguing
Patient groups praise Virginia PDAB veto Read More »
The last time the BIO International Convention was in San Diego, in 2024, Ram May-Ron of the non-dilutive funding specialists FreeMind Group began discussing
BIO 2026: Partnering meetings fill up for industry’s biggest gathering Read More »
Strengthening America’s biopharma manufacturing base and biotechnology leadership are goals both BIO and the Trump administration share. But as companies work to advance those
Section 232 tariff uncertainty remains high as onshoring plan deadline looms Read More »
